Press Releases Silo Pharma, Inc.

Equities

SILO

US82711P2011

Delayed Nasdaq Other stock markets 19:41:22 21/05/2024 BST			5-day change	1st Jan Change
2.2 ^USD	+8.37%		+22.65%	+54.17%

04-23	Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	CI
04-10	Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention	01:45pm	AQ
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine	05-14	AQ
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment	04-23	AQ
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic	04-10	AQ
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic	03-20	AQ
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	03-18	AQ
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD	02-28	AQ
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	02-14	AQ
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	02-01	AQ
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study	01-24	AQ
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD	01-04	AQ
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia	12-28	AQ
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD	11-21	AQ
Silo Pharma : Material Agreement - Form 8-K	11-14	PU
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD	11-08	AQ
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis	16/10/23	AQ
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD	11/10/23	AQ
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA	20/09/23	AQ
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD	12/09/23	AQ
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management	10/08/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Silo Pharma, Inc.

Equities

SILO

US82711P2011

Press Releases

Filters